RSMDF (ResMed) Accounts Payable: $273 Mil (As of Mar. 2026)


RSMDF ResMed Inc RSMDF
94 GF Score
Price $16.72
GF Value $23.97
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Accounts Payable?

ResMed RSMDF 94 Accounts Payable is $273 Mil as of Mar. 2026. GuruFocus rates RSMDF with a GF Score™ of 94/100 and a GF Value™ of $23.97 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ResMed's Accounts Payable for the quarter that ended in Mar. 2026 was $273 Mil.

ResMed's quarterly Accounts Payable declined from Sep. 2025 ($267 Mil) to Dec. 2025 ($250 Mil) but then increased from Dec. 2025 ($250 Mil) to Mar. 2026 ($273 Mil).

ResMed's annual Accounts Payable increased from Jun. 2023 ($151 Mil) to Jun. 2024 ($238 Mil) and increased from Jun. 2024 ($238 Mil) to Jun. 2025 ($278 Mil).

ResMed Accounts Payable Historical Data

* Premium members only.

The historical data trend for ResMed's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Accounts Payable Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 138.01 159.25 150.76 237.73 278.16

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 222.56 278.16 266.78 250.41 273.30
RSMDF
94GF Score
ResMed Inc RSMDF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $273 Mil mean?
ResMed (RSMDF) has a Accounts Payable of $273 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on ResMed and its competitors.
Is ResMed's Accounts Payable too high?
ResMed's current Accounts Payable is $273 Mil. Overall, ResMed has a GF Score™ of 94/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Accounts Payable compare to MDLN and WST?
ResMed's Accounts Payable of $273 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on ResMed and its competitors. ResMed's current Accounts Payable is $273 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (RSMDF) is currently considered Significantly Undervalued. The stock's GF Value™ is $23.97, compared to a current price of $16.72 — trading 30.2% below its estimated fair value. The current Accounts Payable is $273 Mil. ResMed's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For ResMed (RSMDF), the current Accounts Payable is $273 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (RSMDF) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of $16.72 is trading 30.2% below its estimated GF Value™ of $23.97. GuruFocus considers ResMed to be Significantly Undervalued.

Key valuation signals for RSMDF:

  • Accounts Payable: $273 Mil
  • GF Value™: $23.97 vs. price of $16.72 (30.2% below fair value)
  • GF Score™: 94/100 with 1 warning sign

No single metric tells the full story. See the RSMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
94GF Score

Get the complete analysis for RSMDF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.72
Price
$23.97
GF Value